Compare HSTM & PSNL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HSTM | PSNL |
|---|---|---|
| Founded | 1990 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 661.3M | 729.1M |
| IPO Year | 2000 | 2019 |
| Metric | HSTM | PSNL |
|---|---|---|
| Price | $20.19 | $8.57 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $28.00 | $11.33 |
| AVG Volume (30 Days) | 345.6K | ★ 1.4M |
| Earning Date | 02-23-2026 | 02-26-2026 |
| Dividend Yield | ★ 0.61% | N/A |
| EPS Growth | ★ 4.75 | N/A |
| EPS | ★ 0.68 | N/A |
| Revenue | ★ $298,590,000.00 | $69,103,000.00 |
| Revenue This Year | $5.13 | N/A |
| Revenue Next Year | $4.89 | $19.41 |
| P/E Ratio | $29.87 | ★ N/A |
| Revenue Growth | ★ 3.68 | N/A |
| 52 Week Low | $19.50 | $2.83 |
| 52 Week High | $34.24 | $11.50 |
| Indicator | HSTM | PSNL |
|---|---|---|
| Relative Strength Index (RSI) | 35.92 | 47.17 |
| Support Level | $19.50 | $7.95 |
| Resistance Level | $20.54 | $9.04 |
| Average True Range (ATR) | 0.68 | 0.74 |
| MACD | -0.01 | -0.10 |
| Stochastic Oscillator | 22.88 | 39.31 |
HealthStream Inc provides workforce and provider solutions for healthcare organizations. Its reportable segments include Workforce Solutions and Provider Solutions. Workforce development solutions consist of SaaS, subscription-based products that are used by healthcare organizations. Its Provider Solutions products offer healthcare organizations software applications for administering and tracking provider credentialing, privileging, call center and enrollment activities. The company generates a majority of its revenue from Subscription Services.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.